ProShare Advisors’s Ironwood Pharmaceuticals IRWD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$107K Sell
30,474
-5,841
-16% -$23.9K ﹤0.01% 1694
2025
Q4
$122K Buy
36,315
+3,170
+10% +$8.23K ﹤0.01% 1833
2025
Q3
$43.4K Sell
33,145
-5,707
-15% -$5.91K ﹤0.01% 1946
2025
Q2
$27.9K Buy
38,852
+1,007
+3% +$791 ﹤0.01% 2048
2025
Q1
$55.6K Sell
37,845
-12,359
-25% -$29.4K ﹤0.01% 1940
2024
Q4
$222K Buy
50,204
+11,267
+29% +$45.7K ﹤0.01% 1830
2024
Q3
$160K Buy
38,937
+7,764
+25% +$41.7K ﹤0.01% 1787
2024
Q2
$203K Sell
31,173
-7,710
-20% -$54.5K ﹤0.01% 1523
2024
Q1
$339K Buy
38,883
+2,917
+8% +$35.4K ﹤0.01% 1353
2023
Q4
$411K Buy
35,966
+4,703
+15% +$46.5K ﹤0.01% 1164
2023
Q3
$301K Sell
31,263
-348
-1% -$3.41K ﹤0.01% 1206
2023
Q2
$336K Buy
31,611
+1,195
+4% +$12.8K ﹤0.01% 1198
2023
Q1
$320K Sell
30,416
-3,750
-11% -$42K ﹤0.01% 1176
2022
Q4
$423K Buy
34,166
+2,580
+8% +$29.3K ﹤0.01% 1042
2022
Q3
$328K Sell
31,586
-162
-0.5% -$1.84K ﹤0.01% 1095
2022
Q2
$367K Sell
31,748
-12,258
-28% -$144K ﹤0.01% 1093
2022
Q1
$553K Sell
44,006
-11,105
-20% -$127K ﹤0.01% 1221
2021
Q4
$642K Buy
55,111
+1,692
+3% +$20.8K ﹤0.01% 1292
2021
Q3
$698K Sell
53,419
-13,372
-20% -$173K ﹤0.01% 1031
2021
Q2
$860K Buy
66,791
+1,875
+3% +$21.5K ﹤0.01% 1121
2021
Q1
$726K Buy
64,916
+4,855
+8% +$51.3K ﹤0.01% 1188
2020
Q4
$684K Buy
60,061
+14,732
+33% +$161K ﹤0.01% 1077
2020
Q3
$408K Sell
45,329
-1,825
-4% -$18.1K ﹤0.01% 1024
2020
Q2
$487K Buy
47,154
+16,428
+53% +$168K ﹤0.01% 958
2020
Q1
$310K Sell
30,726
-24,021
-44% -$282K ﹤0.01% 864
2019
Q4
$729K Sell
54,747
-5,122
-9% -$56.5K ﹤0.01% 915
2019
Q3
$514K Sell
59,869
-459
-0.8% -$4.46K ﹤0.01% 977
2019
Q2
$660K Sell
60,328
-20,661
-26% -$231K ﹤0.01% 910
2019
Q1
$918K Buy
80,989
+6,637
+9% +$74.1K 0.01% 799
2018
Q4
$645K Sell
74,352
-13,651
-16% -$157K ﹤0.01% 858
2018
Q3
$1.36M Sell
88,003
-3,000
-3% -$47.4K 0.01% 698
2018
Q2
$1.46M Sell
91,003
-5,127
-5% -$75.9K 0.01% 697
2018
Q1
$1.24M Sell
96,130
-14,836
-13% -$185K 0.01% 753
2017
Q4
$1.39M Buy
110,966
+9,082
+9% +$119K 0.01% 722
2017
Q3
$1.35M Buy
101,884
+5,510
+6% +$75.8K 0.01% 660
2017
Q2
$1.52M Sell
96,374
-6,174
-6% -$89.7K 0.02% 626
2017
Q1
$1.47M Sell
102,548
-25,726
-20% -$352K 0.02% 645
2016
Q4
$1.64M Buy
128,274
+13,149
+11% +$166K 0.02% 611
2016
Q3
$1.53M Sell
115,125
-17,963
-13% -$210K 0.02% 565
2016
Q2
$1.46M Buy
133,088
+2,043
+2% +$20K 0.02% 611
2016
Q1
$1.2M Sell
131,045
-12,777
-9% -$105K 0.02% 641
2015
Q4
$1.4M Buy
143,822
+14,119
+11% +$136K 0.02% 624
2015
Q3
$1.13M Sell
129,703
-9,424
-7% -$87.9K 0.02% 640
2015
Q2
$1.41M Sell
139,127
-8,936
-6% -$104K 0.02% 631
2015
Q1
$1.98M Buy
148,063
+19,615
+15% +$257K 0.02% 564
2014
Q4
$1.65M Sell
128,448
-2,586
-2% -$29.6K 0.02% 634
2014
Q3
$1.42M Sell
131,034
-25,123
-16% -$288K 0.02% 914
2014
Q2
$2M Sell
156,157
-79,239
-34% -$862K 0.03% 746
2014
Q1
$2.43M Buy
235,396
+176,041
+297% +$1.98M 0.03% 633
2013
Q4
$577K Sell
59,355
-50,801
-46% -$456K 0.01% 1054
2013
Q3
$1.09M Buy
110,156
+23,969
+28% +$235K 0.03% 805
2013
Q2
$718K Buy
+86,187
New +$1.04M 0.01% 1063

Other funds holding IRWD

ProShare Advisors's IRWD Position: Q1 2026 in Review

ProShare Advisors reduced its Ironwood Pharmaceuticals (IRWD) stake by 16% in Q1 2026, selling an estimated $23.9K and leaving 30,474 shares worth $107K. The position accounts for ﹤0.01% of the portfolio, ranked #1694.

ProShare Advisors first reported a position in IRWD in Q2 2013 and has held it in 52 quarters since. The position peaked at $2.43M in Q1 2014. 226 funds tracked by Wall St. Rank hold IRWD as of Q1 2026.

  • ProShare Advisors held 30,474 shares of Ironwood Pharmaceuticals worth $107K as of Q1 2026.
  • ProShare Advisors sold 5,841 Ironwood Pharmaceuticals shares in Q1 2026, an estimated $23.9K.
  • Ironwood Pharmaceuticals made up ﹤0.01% of ProShare Advisors's portfolio in Q1 2026, its #1694 holding.
  • ProShare Advisors first reported a position in Ironwood Pharmaceuticals in Q2 2013 and has held it in 52 quarters since.
  • ProShare Advisors's Ironwood Pharmaceuticals position peaked at $2.43M in Q1 2014.
  • 226 funds tracked by Wall St. Rank held Ironwood Pharmaceuticals as of Q1 2026.

Based on ProShare Advisors's 13F filing for Q1 2026, filed 27 Apr 2026.